The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its ...
3don MSNOpinion
Moderna chair says US assault on science is just beginning
Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that ...
Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback